Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130052 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL10129943 | 0.81 | — | — | |
| SCHEMBL21211346 | 0.79 | — | — | |
| SCHEMBL17480643 | 0.78 | — | — | |
| SCHEMBL17480642 | 0.78 | — | — | |
| SCHEMBL23325607 | 0.77 | TLR8 (0.33) | — | |
| SCHEMBL6882969 | 0.75 | — | — | |
| SCHEMBL4598342 | 0.74 | — | — | |
| SCHEMBL4598795 | 0.72 | MEN1 (0.33) | — | |
| SCHEMBL6760698 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9533991-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | PTPRB 85/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | PTPRB 1217/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | PTPRB 1217/4885 |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | PTPRB 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.